Pediatric Nephrology

, Volume 20, Issue 6, pp 714–720 | Cite as

Chronic kidney disease and inflammation in pediatric patients: from bench to playground

  • Roberto Pecoits-Filho
  • Lucimary C. Sylvestre
  • Peter Stenvinkel


Signs of an activated immune system can be observed already in the early stages of chronic kidney disease (CKD). Markers of a chronically activated immune system are closely linked to several complications of CKD, such as accelerated atherosclerosis, vascular calcification, insulin resistance, increased muscle catabolism, loss of appetite, bone remodeling, and increased peritoneal permeability. Interestingly, all the aforementioned pathological states resemble a state of accelerated ageing and are strongly associated with increased morbidity and mortality in CKD patients. In recent studies, signs of inflammation have been shown as predictors for mortality in dialysis patients, and the role of inflammation as a risk factor for complications of CKD in children has emerged. Although preliminary findings suggest that inflammation is highly prevalent in the pediatric population with CKD, information related pathogenic links and to clinical outcomes is lacking. For the future, it is crucial for investigations to address the mechanisms and complications of inflammation that are manifested in pediatric patients with CKD in all stages. Since early identification and intervention may generate the most efficient strategies for prevention and treatment of cardiovascular disease in CKD patients, the pediatric population deserves special attention in future studies. In this review, we discuss the mechanisms involved in the inflammatory activation and the main causes and consequences of the inflammatory state observed in the CKD patient, with special emphasis on the pediatric population.


Chronic kidney disease Dialysis Inflammation Cardiovascular disease Children 


  1. 1.
    Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859Google Scholar
  2. 2.
    Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65:1009–1016Google Scholar
  3. 3.
    Stenvinkel P, Pecoits-Filho R, Lindholm B (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14:1927–1939Google Scholar
  4. 4.
    Pecoits-Filho R, Lindholm B, Stenvinkel P (2002) The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant 17 [Suppl 11]:28–31Google Scholar
  5. 5.
    Descamps-Latscha B, Jungers P, Witko-Sarsat V (2002) Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 20:481–484Google Scholar
  6. 6.
    Girndt M, Sester M, Sester U, Kaul H, Kohler H (2001) Molecular aspects of T- and B-cell function in uremia. Kidney Int [Suppl] 78:S206–211Google Scholar
  7. 7.
    Jaber BL, Cendoroglo M, Balakrishnan VS, Perianayagam MC, King AJ, Pereira BJ (2001) Apoptosis of leukocytes: basic concepts and implications in uremia. Kidney Int [Suppl] 78:S197–205Google Scholar
  8. 8.
    Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899–1911Google Scholar
  9. 9.
    Pecoits-Filho R, Lindholm B, Stenvinkel P (2003) End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Eur J Clin Invest 33:527–528Google Scholar
  10. 10.
    Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergstrom J (2002) Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13 [Suppl 1]:S28–36Google Scholar
  11. 11.
    Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B (1996) Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 49:506–511Google Scholar
  12. 12.
    Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P (2002) Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17:1684–1688Google Scholar
  13. 13.
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511Google Scholar
  14. 14.
    Lambert M, Delvin EE, Paradis G, O’Loughlin J, Hanley JA, Levy E (2004) C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem 50:1762–1768Google Scholar
  15. 15.
    Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F (2003) Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111:e382–387Google Scholar
  16. 16.
    Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A (2003) Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. Pediatr Nephrol 18:796–804Google Scholar
  17. 17.
    van der Heijden BJ, van Dijk PC, Verrier-Jones K, Jager KJ, Briggs JD (2004) Renal replacement therapy in children: data from 12 registries in Europe. Pediatr Nephrol 19:213–221Google Scholar
  18. 18.
    Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA (1994) Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45:890–896Google Scholar
  19. 19.
    Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, et al (1995) Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154:882–892Google Scholar
  20. 20.
    Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, Minutolo R, Cuomo V, Guida B, Andreucci M, Rossi G (2000) Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int 58:417–424Google Scholar
  21. 21.
    Bemelmans MH, Gouma DJ, Buurman WA (1993) Influence of nephrectomy on tumor necrosis factor clearance in murine model. J Immunol 150:2007–2017Google Scholar
  22. 22.
    Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J (1990) Fate of injected interleukin 1 in rats: Sequestration and degradation in the kidney. Cytokine 2:416–422Google Scholar
  23. 23.
    Niebauer J, Volk H-d, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJS, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842Google Scholar
  24. 24.
    Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, Lui SF, Sanderson JE (2002) A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 62:639–647Google Scholar
  25. 25.
    Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 14:1614–1622, 2003Google Scholar
  26. 26.
    Rodriguez-Ayla E, Anderstam B, Suliman M, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P (in press) Enhanced RAGE-mediated NFκB stimulation in inflamed hemodialysis patients. AtherosclerosisGoogle Scholar
  27. 27.
    Misselwitz J, Franke S, Kauf E, John U, Stein G (2002) Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol 17:316–321Google Scholar
  28. 28.
    Sebekova K, Podracka L, Heidland A, Schinzel R (2001) Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation—are they inter-related? Clin Nephrol 56:S21–26Google Scholar
  29. 29.
    Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P (2005) Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15:131–136Google Scholar
  30. 30.
    Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimburger O, Lindholm B, Cederholm T, Stenvinkel P (2004) Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80:1222–1229Google Scholar
  31. 31.
    Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in owerweight and obese adults. JAMA 282:2131–2135Google Scholar
  32. 32.
    Owen WF, Lowrie EG (1998) C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627–636Google Scholar
  33. 33.
    Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J (2003) Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 14:1871–1879Google Scholar
  34. 34.
    Yeun JY, Kaysen GA (1997) Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin and peritoneal dialysis patients. Am J Kidney Dis 30:923–927Google Scholar
  35. 35.
    Haubitz M, Schulze M, Koch KM (1990) Increase of C-reactive protein serum values following haemodialysis. Nephrol Dial Transpl 5:500–503Google Scholar
  36. 36.
    Schindler R, Boenisch O, Fischer C, Frei U (2000) Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 53:452–459Google Scholar
  37. 37.
    Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL (1996) Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 49:236–243Google Scholar
  38. 38.
    Lonnemann G (2004) When good water goes bad: how it happens, clinical consequences and possible solutions. Blood Purif 22:124–129Google Scholar
  39. 39.
    Hoenich NA (2003) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 348:1491–1494; author reply 1491–1494Google Scholar
  40. 40.
    Goldstein SL, Currier H, Watters L, Hempe JM, Sheth RD, Silverstein D (2003) Acute and chronic inflammation in pediatric patients receiving hemodialysis. J Pediatr 143:653–657Google Scholar
  41. 41.
    Fujimori A, Naito H, Miyazaki T, Azuma M, Hashimoto S, Horikawa S, Tokukoda Y (1996) Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron 74:471–472Google Scholar
  42. 42.
    Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE Jr, Marcondes M, De Oliveira AH, Noronha IL (2002) Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 17:1480–1486Google Scholar
  43. 43.
    Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, van der Wall Bake AW, van der Sande FM, Leunissen KM (2003) Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 18:797–803Google Scholar
  44. 44.
    Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E (2003) Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298–305Google Scholar
  45. 45.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–119Google Scholar
  46. 46.
    Gruppen MP, Groothoff JW, Prins M, van der Wouw P, Offringa M, Bos WJ, Davin JC, Heymans HS (2003) Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 63:1058–1065Google Scholar
  47. 47.
    Sarnak MJ, Levey AS (2000) Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35:S117–S131Google Scholar
  48. 48.
    Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197Google Scholar
  49. 49.
    Mitsnefes MM (2002) Pediatric end-stage renal disease: heart as a target. J Pediatr 141:162–164Google Scholar
  50. 50.
    Wissler RW, Strong JP (1998) Risk factors and progression of atherosclerosis in youth. PDAY Research Group (pathological determinants of atherosclerosis in youth). Am J Pathol 153:1023–1033Google Scholar
  51. 51.
    Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA (1998) Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338:1650–1656Google Scholar
  52. 52.
    Querfeld U (2002) Is atherosclerosis accelerated in young patients with end-stage renal disease? The contribution of paediatric nephrology. Nephrol Dial Transplant 17:719–722Google Scholar
  53. 53.
    Offner G, Latta K, Hoyer PF, Baum HJ, Ehrich JH, Pichlmayr R, Brodehl J (1999) Kidney transplanted children come of age. Kidney Int 55:1509–1517Google Scholar
  54. 54.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483Google Scholar
  55. 55.
    Querfeld U, Salusky IB, Nelson P, Foley J, Fine RN (1988) Hyperlipidemia in pediatric patients undergoing peritoneal dialysis. Pediatr Nephrol 2:447–452Google Scholar
  56. 56.
    Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB, Baluarte HJ (2000) Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol 14:105–110Google Scholar
  57. 57.
    Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (2000)Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353–362Google Scholar
  58. 58.
    Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105Google Scholar
  59. 59.
    Bennett-Richards KJ, Kattenhorn M, Donald AE, Oakley GR, Varghese Z, Bruckdorfer KR, Deanfield JE, Rees L (2002) Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 62:1372–1378Google Scholar
  60. 60.
    Querfeld U (2004) The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatr Nephrol 19:478–484Google Scholar
  61. 61.
    Sheth RD, Perez MD, Goldstein SL (2003) Cardiovascular calcifications in pediatric patients receiving maintenance dialysis. Pediatr Nephrol 18:810–813Google Scholar
  62. 62.
    Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458–482Google Scholar
  63. 63.
    Besbas N, Ozdemir S, Saatci U, Coskun T, Ozen S, Topaloglu R, Bakkaloglu A, El Nahas AM (1998) Nutritional assessment of children on haemodialysis: value of IGF-I, TNF-alpha and IL-1beta. Nephrol Dial Transplant 13:1484–1488Google Scholar
  64. 64.
    Ekim M, Ikinciogullari A, Ulukol B, Bakkaloglu SA, Ozkaya N, Kendirli T, Adiyaman P, Babacan E, Ocal G (2003) Evaluation of nutritional status and factors related to malnutrition in children on CAPD. Perit Dial Int 23:557–562Google Scholar
  65. 65.
    Wong CS, Hingorani S, Gillen DL, Sherrard DJ, Watkins SL, Brandt JR, Ball A, Stehman-Breen CO (2002) Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney Int 61:630–637Google Scholar
  66. 66.
    Foster BJ, Leonard MB (2004) Measuring nutritional status in children with chronic kidney disease. Am J Clin Nutr 80:801–814Google Scholar
  67. 67.
    Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C (2000) Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 36:811–819Google Scholar
  68. 68.
    Koretz RL (1999) Does nutritional intervention in protein-energy malnutrition improve morbidity or mortality? J Ren Nutr 9:119–121Google Scholar
  69. 69.
    Beddhu S, Zeidel S, Stark S, Saul M, Bruns F (1999) Comorbidity influences the impact of albumin (Alb) on dialysis outcomes. J Am Soc Nephrol 10:234AGoogle Scholar
  70. 70.
    Kaysen GA, Dublin JA, Müller HG, Rosales LM, Levin NW (2000) The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 58:346–352Google Scholar
  71. 71.
    Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15:953–960Google Scholar

Copyright information

© IPNA 2005

Authors and Affiliations

  • Roberto Pecoits-Filho
    • 1
    • 2
  • Lucimary C. Sylvestre
    • 2
  • Peter Stenvinkel
    • 1
  1. 1.Divisions of Renal Medicine and Baxter Novum, Karolinska University Hospital at HuddingeKarolinska InstituteStockholmSweden
  2. 2.Centro de Ciências Biológicas e da SaúdePontifícia Universidade Católica do Paraná CuritibaCuritibaBrazil

Personalised recommendations